HUTCHMED (HCM) advances HMPL-A251 into global solid tumor trials

Rhea-AI Filing Summary

HUTCHMED (CHINA) LIMITED submitted a Form 6-K indicating it issued a press release about starting global clinical development of its ATTC candidate HMPL-A251 in patients with solid tumors. The report is signed by the Chief Financial Officer, Johnny Cheng, and dated December 17, 2025.

Form 6-K: How Foreign Companies Report to the SEC →

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of December 2025

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.	​ ​ ​	Description
​	​	​
Exhibit 99.1	​	Press release relating to the initiation of global clinical development of ATTC candidate HMPL-A251 in patients with solid tumors ​
​	​	​
​	​	​
​	​	​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​	HUTCHMED (CHINA) LIMITED
​	​	​
​	​	​
​	By:	/s/ Johnny Cheng
​	Name:	Johnny Cheng
​	Title:	Chief Financial Officer

​

​

Date: December 17, 2025

3

FAQ

What does HUTCHMED (HCM) disclose in this Form 6-K?

HUTCHMED reports that it issued a press release about beginning global clinical development of ATTC candidate HMPL-A251 in patients with solid tumors. The Form 6-K mainly serves to formally furnish this information to U.S. investors.

What is HMPL-A251 mentioned in HUTCHMED (HCM)'s filing?

HMPL-A251 is described as an ATTC candidate that HUTCHMED is moving into global clinical development for patients with solid tumors. The Form 6-K references a press release focused on this development program but does not provide additional technical details.

When was HUTCHMED (HCM)'s Form 6-K about HMPL-A251 signed?

The Form 6-K was signed on December 17, 2025 on behalf of HUTCHMED (CHINA) LIMITED. It is executed by Johnny Cheng, the company’s Chief Financial Officer, fulfilling the formal requirements under the Securities Exchange Act of 1934.

Who signed HUTCHMED (HCM)'s December 2025 Form 6-K?

The filing is signed by Johnny Cheng, Chief Financial Officer of HUTCHMED (CHINA) LIMITED. His signature confirms the company’s authorization of the report, which furnishes information on the global clinical development of HMPL-A251 in solid tumor patients.

What is included as Exhibit 99.1 in HUTCHMED (HCM)'s Form 6-K?

Exhibit 99.1 is a press release relating to the initiation of global clinical development of ATTC candidate HMPL-A251 in patients with solid tumors. The exhibit provides the primary narrative disclosure referenced by the short Form 6-K cover.